Navigation Links
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Date:11/19/2007

ication of imbalances was observed in serious adverse events between the Nexavar and placebo-treated groups with the most commonly observed adverse events in patients receiving Nexavar being diarrhea and hand-foot skin reaction. Based on these data, the European Commission granted marketing authorization to Nexavar for the treatment of patients with hepatocellular carcinoma on October 29, 2007.

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET. Preclinical models have also demonstrated that Raf/MEK/ERK has a role in HCC; therefore, blocking signaling through Raf-1 may offer therapeutic benefits in HCC.

Important Safety Considerations for U.S. Patients Taking Nexavar

Based on the currently approved package insert for the treatment of patients with unresectable hepatocellular carcinoma, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar vs. 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most common adverse events reported with Nexavar in patients with unresectable HCC were diarrhea, fatigue, weight loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast- feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modificatio
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 16, 2014  Denovo Biopharma, LLC, today announced ... drug, from Eli Lilly and Company (NYSE:  LLY). ... commercialize enzastaurin globally, including transfer of all intellectual ... Lilly developed enzastaurin in a variety ... 3 clinical trials for diffuse large B-cell lymphoma ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011  GP Strategies Corporation (NYSE: GPX ), ... GP Strategies Corporation with and into its ... company structure. General Physics, which is the sole operating ... corporation and will be renamed GP Strategies Corporation when ...
... BOWIE, Md., Dec. 15, 2011  MedAssurant, Inc., ... today announced that Healthcare Partners, IPA (HCPIPA), ... associations (IPA) in the Northeast, has selected ... (CARA™)  solutions to proactively identify gaps in ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... 2014 Recently, iFitDress.com, one of the most ... one shoulder evening gown collection. According to the ... at discounted rates (up to 69% off) at present. Additionally, ... , “I am a frequent caller of your site. ... my dress, I feel quite happy. All items are of ...
(Date:9/16/2014)... 16, 2014 The second federal bellwether ... & Johnson subsidiary Ethicon concluded with the jury in ... and awarding her $3.27 million in damages, according to ... report, “jurors found Ethicon liable for selling faulty devices ... users were at risk from side effects that include ...
(Date:9/16/2014)... forensic techniques are shedding light on a 500-year-old mystery: ... the last English monarch to die in battle? ... whole-body CT scans and micro-CT imaging of injured bones, ... suffered at the Battle of Bosworth Field, where he ... revealed that two skull injuries could have killed the ...
(Date:9/16/2014)... Paradigm Physical Therapy is proud to ... treatment for their patients. Dry needling is a procedure ... of musculoskeletal problems. , In this invasive procedure, a ... skin and muscle to create a trigger point. Using ... helps to deactivate and release the trigger point within ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Paradigm Physical Therapy Introduces Dry Needling 2
... cells (CTCs) may be a promising alternative, noninvasive source ... presented at the Fourth AACR International Conference on Molecular ... idea is that CTCs can provide real-time information about ... biopsy," said Siminder Kaur Atwal, Ph.D., senior research associate ...
... study carried out by Spanish researchers has shown that the ... for good or for bad, the way in which work-related ... manifests itself. Noise-related hearing loss is the most common occupational ... presence of metalworking fluids exhibit a delay in hearing alteration ...
... TUESDAY, Sept. 28 (HealthDay News) -- American middle-school students who ... mentally better off than those who don,t, a new study ... explore the potential health impact that team sports activity might ... ages of 12 and 14. "Other studies have looked ...
... By Steven Reinberg HealthDay Reporter , ... comparison of drug-coated stents -- the metal mesh tubes ... model using the drug sirolimus came out on top, ... coated with zotarolimus, fell short, the study found. ...
... discernible influence on how African American patients with asthma ... study. Researchers found that improved lung function in ... series of baseline breathing function measures, not genetic ancestry. ... of Allergy & Clinical Immunology , http://www.aaaai.org/media/jaci/ ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... Pediatrics doesn,t want children exposed to tobacco ads at ... marketing and advertisements for erectile dysfunction drugs and other ... of the recommendations in its new policy statement, "Children, ...
Cached Medicine News:Health News:Circulating tumor cells can provide 'real-time' information on patient's current disease state 2Health News:Noise and chemicals: Workers are losing their hearing 2Health News:Team Sports Pep Up Middle-School Kids 2Health News:Team Sports Pep Up Middle-School Kids 3Health News:In Test of Stents, Old Standby Wins Out 2Health News:No link between genetic ancestry, asthma response in African-Americans 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 3
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
... greater definition than a standard Galilean ... The Hi-Res five element system provides ... lightweight system., ,Order frame separately., ,Keeler ... in a soft carrying case and ...
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
... Wristrest has become an important standard in busy ... encircles the patient's head and supports arms and ... easy draping especially when fluids are collected. The ... way for easy patient transfer on and off ...
Medicine Products: